Navigation Links
Barr Confirms Patent Challenge of Entocort(R), 3mg Enteric Coated Capsules
Date:5/27/2008

cts in the U.S. and approximately 1,025 products globally outside of the U.S. For more information, visit http://www.barrlabs.com.

Forward-Looking Statements

Except for the historical information contained herein, the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by their use of words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates" and other words of similar meaning. Because such statements inherently involve risks and uncertainties that cannot be predicted or quantified, actual results may differ materially from those expressed or implied by such forward-looking statements depending upon a number of factors affecting the Company's business. These factors include, among others: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the outcome of litigation arising from challenging the validity or non-infringement of patents covering our products; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; the ability of competitors to extend exclusivity periods for their products; our ability to complete product development activities in the timeframes and for the costs we expect; market and customer acceptance and demand for our pharmaceutical products; our dependence on revenues from significant customers; reimbursement policies of third party payors; our dependence on revenues from significant products; the use of estimates in the preparation of our financial statements and our forecasts; the impact of competitive products and pricing on products, including the launch of author
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Kiwa Bio-Tech Confirms Joint Venture Agreement With Shijiazhuang Huaxing Animal Medicine Co., Ltd.
2. Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty
3. Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients
4. U.S. Patent Office Confirms Validity of Osteotechs U.S. Patent No. 5,676,146
5. Research Confirms Better Oil from New DuPont High Oleic Soybean Trait
6. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
7. PPD Confirms Takedas NDA Filing of Alogliptin with U.S. Food and Drug Administration
8. Barr Confirms Patent Challenge of Avodart(R) Soft Gelatin Capsules, 0.5mg
9. Icahn Confirms Intention to Nominate Three Directors at Biogen
10. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
11. Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  ECC West Africa, ... Colorado with University College Hospital (UCH) Ibadan ... development project to finance, design, construct, and operate and ... Nigeria . Under the first of the ... scoping documents and funding applications. UCH Ibadan intends to ...
(Date:7/24/2014)... materialise. Yet, scientists are making progress in devising ... such approach relies on quantum dotsa kind of ... field. A new study demonstrates that changing the ... with electrical impulses can help better control them. ... used as quantum information units, which would produce ...
(Date:7/24/2014)... , July 24, 2014 Research ... "Global Cell Culture Market 2014-2018" report to ... Cell culture is the in vitro growth ... as research, cell studies, and biopharmaceutical production. Cell culture ... production. Cell culture instruments and cell culture consumables are ...
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 /PRNewswire/ ... million, seven-year contract with the National Institute of Allergy ... of Health, to conduct preclinical development of potential therapies ... development of drugs to treat HIV and AIDS and ... as well as microbicides for preventing sexual transmission of ...
Breaking Biology Technology:ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
... 28, 2011 TriLink BioTechnologies, Inc. (TriLink) and Lucigen ... signed a licensing agreement for the use of TriLink,s ... MasterMix. TriLink,s CleanAmp™ dNTPs are an innovative ... standard dNTPs in a PCR assay with CleanAmp™ dNTPs, ...
... SILVER SPRING, Md., July 28, 2011 United Therapeutics Corporation ... for the quarter ended June 30, 2011. "I,m ... quarter, as well as the very good operating results we ... Executive Officer. "We remain on track to reach our 2011 ...
... Mass., July 27, 2011 SomaLogic, Inc. ... today that they have entered into an ... specific SOMAmers as critical and unique reagents ... acid amplification and polymerase chain reaction (PCR) ...
Cached Biology Technology:TriLink BioTechnologies, Inc. Announces License Agreement with Lucigen Corporation 2United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 7Agreement Between SomaLogic and New England Biolabs Enables the Use of SOMAmer Technology for the Optimization of Multiple PCR Products 2
(Date:7/24/2014)... specialist at The University of Texas Health Science Center ... grant to help Harris County residents whose vision problems ... Even with corrective lenses, many people with low vision ... variety of low vision devices, such as telescopes, magnifiers ... , Iyer is using the three-year, $164,645 SightFirst grant ...
(Date:7/24/2014)... week for an all-day public forum on a $1.7 ... to dredge toxic sediment from an eight-mile stretch of ... the plan, which proposes removing 4.3 million cubic yards ... one of the largest cleanups in the agency,s history. ... , "We need to ensure the future well-being of ...
(Date:7/24/2014)... To reduce fire hazard in the United States, wildland ... woody shrubs and suppressed trees (ladder fuels). These ... periods of low fire danger in order to dispose ... hazardous air pollutants, managers often cover all or part ... referred to as agricultural plastic, in order to keep ...
Breaking Biology News(10 mins):UTHealth Dr. Bhavani Iyer awarded low vision grant 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... nanotechnology fanciers suggest that, like proverbial birds of ... or clump together. This tendency, they ... manufacturing increases and the number of nanotechnology-enabled products ... Maynard, chief science advisor to the Project on ...
... completing the first large-scale report sequencing breast and colon ... studied the vast majority of protein-coding genes which now ... mutated in relatively few cancers. Their report, published ... indicates that while little is known about these less-commonly ...
... a reality today, but how can we find out about ... a full record of the Earths climate for several hundred ... that can be taken to the lab for analysis. Incredibly, ... Antarctic regions, and a European Science Foundation programme has a ...
Cached Biology News:Nanoparticle exposures happen, says expert 2Genome update defines landscape of breast and colon cancers 2Genome update defines landscape of breast and colon cancers 3European lead in reading past climates from ice cores 2European lead in reading past climates from ice cores 3
Moue Serum 8-12 Weeks Old...
... is collected off the clot fasted non-Swiss Albino mice ... Available Anticoagulants: N-02: Citrate N-04: ... Potassium Oxalate N-10: EDTA (Na) ... CPD N-09: K3EDTA N-11: ...
Contains 100 positive controls for effective screening of HDAC inhibitors by fluorometric method....
dynactin 4, mRNA (cDNA clone MGC:3248 IMAGE:3505855), complete cds...
Biology Products: